百奧泰(688177.SH):在研藥品BAT6005注射液臨牀試驗獲批
格隆匯7月20日丨百奧泰(688177.SH)公吿,公司於近日收到國家藥品監督管理局核准簽發的關於公司在研藥品BAT6005注射液的《臨牀試驗批准通知書》。
BAT6005是百奧泰開發的具有正常Fc效應功能的IgG1亞型抗TIGIT單克隆抗體,擬開發用於腫瘤治療。TIGIT是一種免疫球蛋白超家族蛋白,高表達於激活的NK細胞、CD4+T細胞、CD8+T細胞以及免疫抑制Tregs細胞表面。
據悉,TIGIT的主要配體PVR高表達於多種實體瘤細胞表面以及樹突狀細胞表面。BAT6005可以阻斷TIGIT與CD155(PVR)的結合,進而恢復T細胞、NK細胞的功能;另外BAT6005具有正常的ADCC效應功能,可以通過ADCC功能清除免疫抑制Tregs細胞。
截至本公吿發布日,全球尚無已獲批上市的TIGIT抗體,但國內已有多個TIGIT抗體正在進行臨牀試驗,未來上市競品和其他潛在競品可能會擁有先行者優勢,BAT6005注射液可能在未來面臨激烈的市場競爭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.